

# ForPatients

by Roche

Type 1 Diabetes Mellitus Diabetic Complication Type 2 Diabetes Mellitus

## The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers

**Trial Status**  
Completed

**Trial Runs In**  
6 Countries

**Trial Identifier**  
NCT02833389 2015-003283-36  
GX29915

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of repeat dosing of UTTR1147A in participants with neuropathic diabetic foot ulcers that do not respond adequately to standard wound care. Participants across multiple sites will be assigned to one of five cohorts (Cohort A, B, C, D, and E) based on the eligibility criteria and randomized to receive subcutaneous (SC) injections of either UTTR1147A or placebo over 12 weeks in addition to standard wound care.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT02833389 2015-003283-36 GX29915**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥ 18 Years

**Healthy Volunteers**  
No

---